Jean‐Philippe Camdessanché

Comparative effectiveness of ofatumumab and ocrelizumab in relapsing multiple sclerosis: a target trial emulation using multinational registry data

Chao Zhu, Sandra Vukusic, Tomáš Kalinčík, Guillaume Mathey et autres

BACKGROUND: Ofatumumab and ocrelizumab are widely used high-efficacy anti-CD20 therapies for relapsing-remitting multiple sclerosis (RRMS), but direct comparative evidence remains limited. We aimed to compare their effectiveness in routine clinical practice. METHODS: We conducted an observational cohort study emulating a target trial …

au, fr, cz, tr, hr, ir, es, nl, mx, be, ca, it, kw, si, mq (code pays fourni par la source)

SLA : la pluridisciplinarité dans l’accompagnement du patient et de son entourage

Marie-Édith Giraud, Jean‐Philippe Camdessanché, Nathalie Dimier, Marie Carroz

fr (code pays fourni par la source)

Tick-borne encephalitis emergence as the third leading cause of encephalitis/meningoencephalitis in western Auvergne-Rhône-Alpes, France

Emilie Mayer, Aurélie Velay, Céline Cazorla, Nazli Ayhan et autres

OBJECTIVES: In 2017, the first autochthonous cases of tick-borne encephalitis (TBE) were reported in the region of Saint-Étienne, a forested and mountainous area in Auvergne-Rhône-Alpes (AURA), France. We aimed to describe the frequency of TBE among patients in this area with acute …

fr, us (code pays fourni par la source)

Characteristics of Patients with Myasthenia Gravis in the French Rare Disease Registry

Jean‐Philippe Camdessanché, Andoni Echaniz‐Laguna, Guilhem Solé, C. Blein et autres

BACKGROUND: The French National Rare Diseases Registry (BNDMR) was established in 2007 to ensure access to optimal care standards for all patients with rare diseases in dedicated reference centres. The objective of this retrospective cohort study was to describe patients with myasthenia …

fr, be (code pays fourni par la source)

Leucoencéphalopathie avec atteinte du tronc cérébral et de la moelle épinière : n’oubliez pas DARS2

Mélany Venet, Francis Ramond, Mekki Amine, Jean‐Philippe Camdessanché

fr (code pays fourni par la source)

Apport du dosage des neurofilaments (NfL) dans le sang pour le diagnostic et le pronostic de la sclérose latérale amyotrophique

Oriane Gourhand, Jean‐Philippe Camdessanché, Nathalie Guy, Annaïck Desmaison

fr (code pays fourni par la source)

Neuropathies associées aux anticorps anti-FGFR3 : quelle évolution et quels traitements 10 ans plus tard ?

J.L. Michel, Yannick Tholance, Françoise Bouhour, François Lassablière et autres

fr (code pays fourni par la source)

Intérêt du monitoring des anticorps anti-RAC chez les patients myasthéniques et corrélation avec le statut clinique

Myriam Charai, Jean‐Philippe Camdessanché

fr (code pays fourni par la source)

Évaluation d’un examen neurologique numérique multimodal pour prédire l’évolution progressive des patients atteints de sclérose en plaques rémittente recevant un traitement de haute efficacité

Aurélie Hohweiller, Mickaël Cohen, Jean‐Philippe Camdessanché, Christine Lebrun-Frenay

fr (code pays fourni par la source)

Influence of geographical accessibility to specialist and primary care givers on excess mortality of multiple sclerosis patients in France

Sarah M. Wilson, Emmanuelle Leray, Floriane Calocer, Fabien Rollot et autres

BACKGROUND: Access to healthcare and socioeconomic deprivation are intricately linked. No studies have been led to measure the effect of healthcare accessibility on mortality in patients with MS so far. The objective was to examine the influence of travel time to the …

fr, lu (code pays fourni par la source)

Evaluating MRI-Confirmed Relapses as a Novel Primary Endpoint in Multiple Sclerosis Trials

Antoine Gavoille, Stanislas Demuth, Mikaïl Nourredine, Igor Faddeenkov et autres

Abstract Background Clinically defined relapses are the traditional primary endpoint of randomized control trials (RCTs) in multiple sclerosis (MS), yet a substantial proportion lack new inflammatory lesions. Confirming relapses with brain and spinal cord MRI to distinguish relapses with active MRI (RAM) …

fr, ch (code pays fourni par la source)

Inter-laboratory comparison of a serum fibroblast growth factor receptor 3 (FGFR3) antibody test in sensory neuropathies

Luise Appeltshauser, Christian P. Moritz, Lena Reinhardt, Luisa Kreß et autres

Introduction: Autoantibodies against fibroblast growth factor receptor 3 (FGFR3) have been suggested as a diagnostic marker in both sensory large and small fiber neuropathy. Yet, their clinical relevance remains unclear and no standardized protocols for antibody testing exist. Here, we evaluate an …

de, fr (code pays fourni par la source)